Cargando…

Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes

Novel chemical controls are needed that selectively target human, animal, and plant parasitic nematodes with reduced adverse effects on the host or the environment. We hypothesize that the phosphodiesterase (PDE) enzyme family represents a potential target for development of novel nematicides and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuster, Kevin D., Mohammadi, Mohammadjavad, Cahill, Karyn B., Matte, Suzanne L., Maillet, Alexis D., Vashisth, Harish, Cote, Rick H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436744/
https://www.ncbi.nlm.nih.gov/pubmed/30917179
http://dx.doi.org/10.1371/journal.pone.0214554
_version_ 1783406852479909888
author Schuster, Kevin D.
Mohammadi, Mohammadjavad
Cahill, Karyn B.
Matte, Suzanne L.
Maillet, Alexis D.
Vashisth, Harish
Cote, Rick H.
author_facet Schuster, Kevin D.
Mohammadi, Mohammadjavad
Cahill, Karyn B.
Matte, Suzanne L.
Maillet, Alexis D.
Vashisth, Harish
Cote, Rick H.
author_sort Schuster, Kevin D.
collection PubMed
description Novel chemical controls are needed that selectively target human, animal, and plant parasitic nematodes with reduced adverse effects on the host or the environment. We hypothesize that the phosphodiesterase (PDE) enzyme family represents a potential target for development of novel nematicides and anthelmintics. To test this, we identified six PDE families present in the nematode phylum that are orthologous to six of the eleven human PDE families. We characterized the binding interactions of family-selective PDE inhibitors with human and C. elegans PDE4 in conjunction with molecular dynamics (MD) simulations to evaluate differences in binding interactions of these inhibitors within the PDE4 catalytic domain. We observed that roflumilast (human PDE4-selective inhibitor) and zardaverine (selective for human PDE3 and PDE4) were 159- and 77-fold less potent, respectively, in inhibiting C. elegans PDE4. The pan-specific PDE inhibitor isobutyl methyl xanthine (IBMX) had similar affinity for nematode and human PDE4. Of 32 residues within 5 Å of the ligand binding site, five revealed significant differences in non-bonded interaction energies (van der Waals and electrostatic interaction energies) that could account for the differential binding affinities of roflumilast and zardaverine. One site (Phe506 in the human PDE4D3 amino acid sequence corresponding to Tyr253 in C. elegans PDE4) is predicted to alter the binding conformation of roflumilast and zardaverine (but not IBMX) into a less energetically favorable state for the nematode enzyme. The pharmacological differences in sensitivity to PDE4 inhibitors in conjunction with differences in the amino acids comprising the inhibitor binding sites of human and C. elegans PDE4 catalytic domains together support the feasibility of designing the next generation of anthelmintics/nematicides that could selectively bind to nematode PDEs.
format Online
Article
Text
id pubmed-6436744
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64367442019-04-12 Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes Schuster, Kevin D. Mohammadi, Mohammadjavad Cahill, Karyn B. Matte, Suzanne L. Maillet, Alexis D. Vashisth, Harish Cote, Rick H. PLoS One Research Article Novel chemical controls are needed that selectively target human, animal, and plant parasitic nematodes with reduced adverse effects on the host or the environment. We hypothesize that the phosphodiesterase (PDE) enzyme family represents a potential target for development of novel nematicides and anthelmintics. To test this, we identified six PDE families present in the nematode phylum that are orthologous to six of the eleven human PDE families. We characterized the binding interactions of family-selective PDE inhibitors with human and C. elegans PDE4 in conjunction with molecular dynamics (MD) simulations to evaluate differences in binding interactions of these inhibitors within the PDE4 catalytic domain. We observed that roflumilast (human PDE4-selective inhibitor) and zardaverine (selective for human PDE3 and PDE4) were 159- and 77-fold less potent, respectively, in inhibiting C. elegans PDE4. The pan-specific PDE inhibitor isobutyl methyl xanthine (IBMX) had similar affinity for nematode and human PDE4. Of 32 residues within 5 Å of the ligand binding site, five revealed significant differences in non-bonded interaction energies (van der Waals and electrostatic interaction energies) that could account for the differential binding affinities of roflumilast and zardaverine. One site (Phe506 in the human PDE4D3 amino acid sequence corresponding to Tyr253 in C. elegans PDE4) is predicted to alter the binding conformation of roflumilast and zardaverine (but not IBMX) into a less energetically favorable state for the nematode enzyme. The pharmacological differences in sensitivity to PDE4 inhibitors in conjunction with differences in the amino acids comprising the inhibitor binding sites of human and C. elegans PDE4 catalytic domains together support the feasibility of designing the next generation of anthelmintics/nematicides that could selectively bind to nematode PDEs. Public Library of Science 2019-03-27 /pmc/articles/PMC6436744/ /pubmed/30917179 http://dx.doi.org/10.1371/journal.pone.0214554 Text en © 2019 Schuster et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Schuster, Kevin D.
Mohammadi, Mohammadjavad
Cahill, Karyn B.
Matte, Suzanne L.
Maillet, Alexis D.
Vashisth, Harish
Cote, Rick H.
Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes
title Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes
title_full Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes
title_fullStr Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes
title_full_unstemmed Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes
title_short Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes
title_sort pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode pde4: implications for management of parasitic nematodes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436744/
https://www.ncbi.nlm.nih.gov/pubmed/30917179
http://dx.doi.org/10.1371/journal.pone.0214554
work_keys_str_mv AT schusterkevind pharmacologicalandmoleculardynamicsanalysesofdifferencesininhibitorbindingtohumanandnematodepde4implicationsformanagementofparasiticnematodes
AT mohammadimohammadjavad pharmacologicalandmoleculardynamicsanalysesofdifferencesininhibitorbindingtohumanandnematodepde4implicationsformanagementofparasiticnematodes
AT cahillkarynb pharmacologicalandmoleculardynamicsanalysesofdifferencesininhibitorbindingtohumanandnematodepde4implicationsformanagementofparasiticnematodes
AT mattesuzannel pharmacologicalandmoleculardynamicsanalysesofdifferencesininhibitorbindingtohumanandnematodepde4implicationsformanagementofparasiticnematodes
AT mailletalexisd pharmacologicalandmoleculardynamicsanalysesofdifferencesininhibitorbindingtohumanandnematodepde4implicationsformanagementofparasiticnematodes
AT vashisthharish pharmacologicalandmoleculardynamicsanalysesofdifferencesininhibitorbindingtohumanandnematodepde4implicationsformanagementofparasiticnematodes
AT coterickh pharmacologicalandmoleculardynamicsanalysesofdifferencesininhibitorbindingtohumanandnematodepde4implicationsformanagementofparasiticnematodes